Last reviewed · How we verify
Adbry (TRALOKINUMAB)
Adbry blocks the action of IL-13, a protein that contributes to inflammation and skin barrier disruption in atopic dermatitis.
Adbry (Tralokinumab) is a small molecule Interleukin-13 antagonist developed by LEO PHARMA AS, targeting the IL-13 pathway to treat moderate to severe atopic dermatitis. It was FDA approved in 2021 and is currently owned by LEO PHARMA AS. Adbry works by blocking the action of IL-13, a protein involved in inflammation and skin barrier disruption. As a patented medication, Adbry is not yet available as a generic. Key safety considerations include the potential for increased risk of infections and allergic reactions.
At a glance
| Generic name | TRALOKINUMAB |
|---|---|
| Sponsor | Leo Pharma As |
| Drug class | Interleukin-13 Antagonist [EPC] |
| Target | Interleukin-13 |
| Modality | Monoclonal antibody |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2021 |
Mechanism of action
Tralokinumab-ldrm is human IgG4 monoclonal antibody that specifically binds to human interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor and subunits (IL-13R1 and IL-13R2). IL-13 is naturally occurring cytokine of the Type immune response. Tralokinumab-ldrm inhibits the bioactivity of IL-13 by blocking IL-13 interaction with IL-13R1/IL-4R receptor complex. Tralokinumab-ldrm inhibits IL-13-induced responses including the release of proinflammatory cytokines, chemokines and IgE.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- Upper respiratory tract infections
- Conjunctivitis
- Injection site reactions
- Eosinophilia
- Keratitis
Key clinical trials
- A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis (PHASE3)
- Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact
- Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation (PHASE2,PHASE3)
- Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) (PHASE2)
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Registry for Systemic Eczema Treatments
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (PHASE3)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adbry CI brief — competitive landscape report
- Adbry updates RSS · CI watch RSS
- Leo Pharma As portfolio CI